857 results match your criteria: "University Hospital "G.Rodolico"[Affiliation]"
Am J Epidemiol
September 2024
Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate net survival, cure fraction, time to cure (when 5-year conditional net survival becomes > 95%), cure prevalence (women who will not die of cancer), and already cured (living longer than time to cure).
View Article and Find Full Text PDFCirc Cardiovasc Interv
April 2024
Heart Institute (InCor), University of São Paulo Medical School, Brazil (C.M.C., L.A.H., R.K.F., A.A.).
Background: Oncological patients with coronary artery disease face an elevated risk of hemorrhagic and ischemic events following percutaneous coronary intervention. Despite medical guidelines recommending minimal dual antiplatelet therapy (DAPT) duration for patients with cancer, dedicated data on abbreviated DAPT in this population is lacking. This study aims to evaluate the occurrence of ischemic and hemorrhagic events in patients with cancer compared with other high-bleeding risk individuals.
View Article and Find Full Text PDFCirc Cardiovasc Interv
April 2024
The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY (A.S., S.L.K., R.M.).
Dual antiplatelet therapy-the combination of aspirin and a P2Y12 inhibitor-remains the standard antiplatelet regimen recommended to prevent ischemic complications immediately after percutaneous coronary intervention. Nonetheless, recent advances in stent technologies, percutaneous coronary intervention techniques, adjunctive pharmacotherapy for secondary prevention, and the rising awareness of the prognostic impact of bleeding, which are inevitably associated with dual antiplatelet therapy, led to the investigation of alternative antiplatelet regimens related to fewer bleeding and a preserved ischemic protection. Thrombotic complications occur mostly in the first months after percutaneous coronary intervention, while the risk of bleeding remains stable over time; this observation laid the foundation of the concept of antiplatelet de-escalation, consisting of a more intense antiplatelet regimen early after percutaneous coronary intervention, followed by a less potent antiplatelet therapy thereafter.
View Article and Find Full Text PDFAnn Hematol
September 2024
Hematology and BMT Unit, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico-San Marco", Catania, Italy.
Blinatumomab is a bispecific T-cell engager approved for relapsed/refractory and minimal residual disease positive B-cell Acute Lymphoblastic Leukemia. We conducted a retrospective study evaluating the outcome of Blinatumomab. The impact of clinical and treatment-related variables on cumulative incidence of relapse/progression (CIRP), event-free (EFS) and overall survival (OS) was analyzed.
View Article and Find Full Text PDFBrain Spine
March 2024
Functional Neurosurgery Unit, Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
Introduction: Spinal cord stimulation is a widespread treatment of chronic neuropathic pain from different conditions. Several novel and improving technologies have been recently developed to increase the effect of neuromodulation in patients refractory to pharmacological therapy.
Research Question: To explore spinal cord stimulation's mechanisms of action, indications, and management.
J Anesth Analg Crit Care
April 2024
Policlinico G. Rodolico - San Marco University Hospital, Catania, Italy.
Background: Propofol is the most commonly used hypnotic agent used during sedation and general anesthesia (GA) practice, offering faster recovery compared to benzodiazepines. However, cardiovascular impact of propofol and pain at injection are commonly encountered side effects. Ciprofol is a novel disubstituted phenol derivative, and there is growing evidence regarding its clinical use.
View Article and Find Full Text PDFMol Diagn Ther
May 2024
Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125, Catania, Italy.
Respir Care
October 2024
Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; and Department of Anesthesiology, McMaster University, Hamilton, Ontario, Canada.
Background: Home noninvasive ventilation (NIV) may improve chronic hypercarbia in COPD and patient-important outcomes. The efficacy of home high-flow nasal cannula (HFNC) as an alternative is unclear.
Methods: We searched MEDLINE, Embase, Cochrane CENTRAL, Scopus, and ClinicalTrials.
J Neurol Neurosurg Psychiatry
October 2024
University Hospital Ghent, Gent, Belgium.
Background: It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course.
Methods: This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis.
Catheter Cardiovasc Interv
May 2024
Interventional Radiology Unit, Endovascular Interventions & Research, Foot & Ankle Clinic, Policlinico, Abano Terme, Italy.
EuroIntervention
April 2024
Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
Pulmonary embolism (PE) ranks as a leading cause of in-hospital mortality and the third most common cause of cardiovascular death. The spectrum of PE manifestations varies widely, making it difficult to determine the best treatment approach for specific patients. Conventional treatment options include anticoagulation, thrombolysis, or surgery, but emerging percutaneous interventional procedures are being investigated for their potential benefits in heterogeneous PE populations.
View Article and Find Full Text PDFInt J Cardiol
July 2024
Cardio-Thoracic and Vascular Department, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy; Department of Vascular Physiopathology, IRCCS Neuromed, Pozzilli (IS), Italy. Electronic address:
Radiol Case Rep
June 2024
Department of Medical Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania -Radiology I Unit, University Hospital Policlinico "G. Rodolico-San Marco", Via Santa Sofia 78, 95123 Catania, Italy.
Extramedullary hematopoiesis represents a clinical compensatory condition characterized by the growth of hematopoietic tissue outside the bone marrow. It can mainly occur in patient with myeloproliferative disorders where alteration or neoplastic invasion of the bone marrow causes ineffective production of blood cells with the recruitment of progenitrix blood cells in non-hematopoietic organs, including kidneys. Renal extramedullary hematopoiesis is a rare condition manifesting as parenchymal or perirenal soft tissue masses with different patterns mimicking neoplasms, infectious or vascular diseases.
View Article and Find Full Text PDFAbdom Radiol (NY)
September 2024
Radiology Unit 1, Department of Medical Surgical Sciences and Advanced Technologies "GF Ingrassia", University Hospital Policlinico "G. Rodolico-San Marco", 95123, Catania, Italy.
Lancet Child Adolesc Health
May 2024
CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address:
Background: High-efficacy disease-modifying therapies have been proven to slow disability accrual in adults with relapsing-remitting multiple sclerosis. However, their impact on disability worsening in paediatric-onset multiple sclerosis, particularly during the early phases, is not well understood. We evaluated how high-efficacy therapies influence transitions across five disability states, ranging from minimal disability to gait impairment and secondary progressive multiple sclerosis, in people with paediatric-onset multiple sclerosis.
View Article and Find Full Text PDFLife (Basel)
February 2024
Department of Anesthesia and Intensive Care, University Hospital Policlinico "G. Rodolico-San Marco", 95123 Catania, Italy.
In an era where modern medicine has made remarkable advances in managing diseases in the head and neck region, we present this Special Issue to provide a spotlight on the new research advances on olfactory and gustatory disorders [...
View Article and Find Full Text PDFCancers (Basel)
March 2024
Dipartimento Onco-Ematologico, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy.
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use, and clinical outcomes in 309 patients with CLL receiving single-agent ibrutinib in first line (1L, = 118), 2L ( = 127) and ≥3L ( = 64) in the prospective, real-world, Italian EVIdeNCE study. After a median follow-up of 23.
View Article and Find Full Text PDFMinerva Med
April 2024
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy -
J Am Heart Assoc
April 2024
Department of Cardiology ASL2 Abruzzo Chieti Italy.
Int J Cancer
July 2024
Epidemiological Department, Azienda Zero, Padua, Italy.
People alive many years after breast (BC) or colorectal cancer (CRC) diagnoses are increasing. This paper aimed to estimate the indicators of cancer cure and complete prevalence for Italian patients with BC and CRC by stage and age. A total of 31 Italian Cancer Registries (47% of the population) data until 2017 were included.
View Article and Find Full Text PDFInt J Cardiol
July 2024
Heart Failure Working Group, Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Florence, Italy; Department of Cardiovascular Sciences Cardiology, Ospedali Riuniti, Ancona, Italy.
Background: Available data on the clinical characteristics and prognosis of patients with heart failure (HF) due to dilated cardiomyopathy (DCM) derive mainly from tertiary care centres for cardiomyopathies or from drug trial sub-studies, which may entail a referral bias.
Methods: From 2008 to 2021, we enrolled in a nationwide HF Registry 1886 DCM patients and 3899 with ischemic heart disease (IHD).
Results: Patients with DCM were younger, more often female, had more commonly recent onset HF, left bundle branch block, and showed higher LV end-diastolic volume and lower LVEF than IHD.
EuroIntervention
March 2024
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany and DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany.
ERJ Open Res
March 2024
IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
https://bit.ly/46XMWAz.
View Article and Find Full Text PDFEur J Pediatr
June 2024
Neonatal Intensive Care Unit, Clínica Universidad de Navarra, 28027, Madrid, Spain.
Unlabelled: Neonates face heightened susceptibility to drug toxicity, often exposed to off-label medications with dosages extrapolated from adult or pediatric studies. Premature infants in Neonatal Intensive Care Units (NICUs) are particularly at risk due to underdeveloped pharmacokinetics and exposure to multiple drugs. The study aimed to survey commonly used medications with a higher risk of ototoxicity and nephrotoxicity in Spanish and Italian neonatal units.
View Article and Find Full Text PDFClin Exp Rheumatol
February 2024
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.